Effectiveness of Inspiratory Muscle Training on Sleep in Patients With Obstructive Sleep Apnea
- Conditions
- Obstructive Sleep Apnea (OSA)Sleep
- Registration Number
- NCT07149233
- Lead Sponsor
- Universidade Federal de Pernambuco
- Brief Summary
The goal of this clinical trial is to evaluate the effectiveness of inspiratory Muscle Training (IMT) on both objective and subjective sleep parameters in patients with OSA.Methods: A prospective, randomized, controlled clinical trial will be conducted with patients diagnosed with OSA followed at Otavio de Freitas Hospital. Participants will be evaluated for excessive daytime sleepiness (Epworth Sleepiness Scale), sleep quality (Pittsburgh Sleep Quality Index), physical activity level (IPAQ), sleep latency, total sleep time, sleep efficiency, number of nocturnal awakenings, total time in bed, total wake time during sleep (Actigraphy), hypoxic burden during sleep (Nocturnal Oximetry), disease severity (Polysomnography), respiratory muscle strength (Manovacuometry), and respiratory muscle endurance (Powerbreathe K-series) before and after 4 weeks of training, as well as perceived change in health status after IMT (PGIC).Participants will be divided into two groups and will perform IMT for 4 weeks: the experimental group will perform IMT with a progressive weekly load (50%, 60%, 75% of MIP) adjusted using the Powerbreathe® Classic device, while the control group will use the device without load. The participants will perform IMT at home under the guidance of the principal investigator.Statistical Analysis: Data will be analyzed using SPSS version 26.0 with descriptive and analytical statistical techniques. Normality will be assessed using the Shapiro-Wilk test. For intergroup and intragroup comparisons, two-way ANOVA will be used. Tukey's post-hoc test will be applied to compare pre- and post-intervention mean variances for each group. The level of significance adopted for all analyses will be 95% (p \< 0.05).Expected Results: It is expected that 4 weeks of IMT in patients with OSA will reduce excessive daytime sleepiness, sleep latency, number of awakenings, and hypoxic burden, as well as increase sleep efficiency and total sleep time, leading to improved sleep quality.
- Detailed Description
Obstructive Sleep Apnea (OSA) is a prevalent sleep-related breathing disorder characterized by repeated episodes of upper airway obstruction during sleep, leading to intermittent hypoxia, sleep fragmentation, and frequent arousals. These events disrupt sleep architecture, reduce total sleep time and sleep efficiency, and result in non-restorative sleep. As a consequence, patients often present with excessive daytime sleepiness, cognitive and functional impairments, and an increased risk of occupational errors and motor vehicle accidents.
The impact of OSA extends beyond sleep, contributing to reduced quality of life and increased cardiovascular and metabolic risks. Considering the multifactorial consequences of OSA and the barriers to continuous positive airway pressure (CPAP) adherence-including cost, discomfort, and access-there is a need for alternative or adjunctive low-cost therapies that are easy to implement and have proven efficacy.
Inspiratory Muscle Training (IMT) has emerged as a promising therapeutic strategy to improve respiratory muscle strength, reduce symptoms, and potentially enhance sleep quality. However, evidence regarding its impact on objective and subjective sleep parameters in patients with OSA remains limited.
This study aims to evaluate the efficacy of a 4-week IMT protocol, following standardized training guidelines, in adults with moderate to severe OSA who have not yet initiated CPAP therapy. Validated instruments will be used to assess sleep outcomes. The findings are expected to contribute to clinical decision-making and offer evidence for non-pharmacological, non-invasive interventions to improve sleep quality and reduce daytime symptoms in this population.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 30
- Male or female participants
- Age between 18 and 70 years
- Clinical diagnosis of moderate to severe Obstructive Sleep Apnea (OSA), confirmed by polysomnography
- Not currently undergoing treatment for OSA
- Presence of neuromuscular disorders, infectious diseases, immunological conditions, tumors, or any disease that prevents inspiratory muscle training (IMT), manovacuometry, or respiratory muscle performance assessment
- Unstable angina, untreated or uncontrolled systemic arterial hypertension, left ventricular dysfunction, cerebral aneurysm, or any cardiovascular condition contraindicating IMT or respiratory muscle testing
- Upper limb deformities that prevent the use of actigraphy devices or oximetry sensors
- Other sleep disorders (e.g., insomnia, hypoventilation syndrome, or need for continuous home oxygen therapy)
- Cognitive impairment that limits the participant's ability to understand or follow study procedures
- Ongoing or planned CPAP therapy during the follow-up period
- Participation in a pulmonary rehabilitation program within 6 months prior to the study
- Moderate or high physical activity level according to the IPAQ, including regular moderate or vigorous physical activity within the past 30 days
- Use of sleep-inducing medication to treat insomnia
- Grade 2 or 3 obesity (BMI ≥ 35 kg/m²)
- Residence in a geographic area with limited or no access to telephone or internet service, preventing contact or data transmission from study devices (actigraphy and/or oximetry sensors)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method sleep quality Sleep quality will be assessed before and after four weeks of inspiratory muscle training Sleep quality will be assessed using the PSQI. A score from 0 to 4 indicates good sleep quality, while a score above 5 indicates poor sleep quality
daytime sleepiness Daytime sleepiness will be assessed before and after four weeks of inspiratory muscle training Daytime sleepiness will be assessed using the Epworth Sleepiness Scale (ESS) before and after the four weeks of inspiratory muscle training (IMT). The scale consists of eight everyday situations, asking the individual to self-assess the likelihood of dozing off during these activities, scoring from 0 to 3, where 0: no chance of dozing, 1: slight chance, 2: moderate chance, and 3: high chance. A total score greater than 10 is used as the cutoff point to identify individuals with a high likelihood of excessive daytime sleepiness
- Secondary Outcome Measures
Name Time Method hypoxic burden The hypoxic burden will be assessed before and after four weeks of inspiratory muscle training To assess peripheral oxygen saturation (SpO2) levels during sleep, a sleep study will be conducted using a high-resolution wireless pulse oximeter. The collected data are automatically transferred to a cloud service where they are analyzed by an algorithm.
Maximal Inspiratory Pressure (MIP) Baseline, weekly during intervention (for load adjustment), and post-intervention (4 weeks) Inspiratory muscle strength assessed by POWERbreathe KH2 in testing mode. The evaluation will be performed weekly during the intervention period to adjust training loads, and at baseline and post-intervention for analysis purposes; Unit of measure: cmH₂O
; Assessment tool: POWERbreathe KH2/K5Disease severity Disease severity will be assessed before and after four weeks of inspiratory muscle training. Disease severity will be assessed through polygraphy before and after the four weeks of inspiratory muscle training (IMT) in the study participants. The ApneaLink device (ResMed) will be used to evaluate disease severity
Physical activity level Assessment Before and after 4 weeks Physical activity level will be assessed using the International Physical Activity Questionnaire (IPAQ), an instrument that estimates weekly energy expenditure from physical activities related to work, transportation, household tasks, and leisure.The IPAQ classification divides and defines physical activity levels into the following categories: low, moderate, or high
Respiratory endurance Assessment Before and after 4 weeks Unit of measurement: (cmH₂O); Assessment tool: Powerbreathe KH2/K5
Fatigue Index Strength Assessment Before and after 4 weeks Unit of measurement: (cmH₂O); Assessment tool: Powerbreathe KH2/K5
Peak inspiratory flow Assessment Before and after 4 weeks Unit of measurement: (liters/second); Assessment tool: Powerbreathe KH2/K5
Energy inspiratory Assessment Before and after 4 weeks Unit of measurement: (joules); Assessment tool: Powerbreathe KH2/K5
Volume inspiratory Assessment Before and after 4 weeks Unit of measurement: (liters); Assessment tool: Powerbreathe KH2/K5
Bedtime 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Bedtime assessed objectively by actigraphy; Unit of measure: hours ;Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Wake-up time 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Wake-up time assessed objectively by actigraphy; Unit of measure: hours; Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Sleep latency 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol nterval between bedtime and sleep onset measured by actigraphy.
nterval between bedtime and sleep onset measured by actigraphy; Unit of measure: minutes (min); Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)Sleep efficiency 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Percentage of total sleep time (TST) divided by time in bed (TIB), derived from actigraphy; Unit of measure: percentage (%); Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Total sleep time (TST) 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Total time spent asleep measured by actigraphy; Unit of measure: hours (h); Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Time in bed (TIB) 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Total time in bed measured by actigraphy; Unit of measure: hours (h);
Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)Number of awakenings after sleep onset 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Number of awakenings after sleep onset measured by actigraphy; Unit of measure: count (n); Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Number of secondary sleep episodes after sleep onse 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Number of additional sleep episodes after initial sleep onset measured by actigraphy; Unit of measure: count (n); ssessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Wake after sleep onset (WASO) 9 days before the start of IMT and 9 days after completion of the 4-week IMT protocol Minutes of wakefulness after sleep onset measured by actigraphy; Unit of measure: minutes (min); Assessment tool: ActTrust actigraph (Condor Instruments, Brazil)
Maximal Expiratory Pressure (MEP) Assessment Before and after 4 weeks Maximum expiratory pressure at the mouth during a maximal effort against occluded airway; Unit of measure: cmH₂O
Assessment tool: HOMED MVD300 digital manovacuometer
Trial Locations
- Locations (1)
Cardiopulmonary Physiotherapy Laboratory
🇧🇷Recife, Pernambuco, Brazil
Cardiopulmonary Physiotherapy Laboratory🇧🇷Recife, Pernambuco, Brazil